- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Tatva Chintan Pharma Chem (TCPCL) delivered strong Q1 FY27 results. Revenue from operations jumped 43% year-over-year (YoY) to ₹167.1 Cr. Profit After Tax (PAT) surged 140% YoY to ₹16 Cr, with EBITDA growing 86% YoY to ₹32.3 Cr. Key revenue drivers included Pharma & Agrochemical Intermediates (PASC) at 35%, Structure Directing Agents (SDA) at 34%, and Phase Transfer Catalysts (PTC) at 26%.
TCPCL's strategy focuses on "green chemistry" processes like electrolysis and continuous flow chemistry for higher efficiency and lower waste. This R&D-driven approach, combined with a diverse product portfolio, underpins its competitive advantage.
The company recently commenced commercial production at its expanded Dahej SEZ facility, boosting its combined reactor capacity to 791KL and 39 Assembly Lines.
Key Financials (Q1 FY27):
* Revenue: ₹167.1 Cr (+43% YoY)
* PAT: ₹16 Cr (+140% YoY)
* EPS: ₹6.83
* EBITDA: ₹32.3 Cr (+86% YoY)
Management anticipates continued growth by leveraging its niche in specialty chemicals, capitalizing on global supply chain shifts, and focusing on sustainable manufacturing.